Tibulizumab
Based on 1 Customer Validation
Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting B-cell activating factor (BAFF) and IL-17A with Kd values of 60 pM and 14 pM, respectively. Tibulizumab can be used for autoimmune disease research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98.86%
- CAS No.: 1849636-24-3
- Masse moléculaire:201.43 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Description
Isotype
IgG4-kappa-[scFv-heavy-kappa]2
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-17A 14 pM (Kd) |
BAFF 60 pM (Kd) |
In Vitro
Tibulizumab (LY 3090106) binds to mouse BAFF with a KD of 340 nM and does not bind to mouse IL-17. Tibulizumab binds to cynomolgus BAFF and cynomolgus IL-17 with KD of 26.8 pM and 19 pM, respectively[1].
In HT-29 cells, Tibulizumab antagonizes the IL-17-induced secretion of CXCL1 in a concentration-dependent manner (IC50 of 2.00 nM). In T1165 cells, Tibulizumab blocks BAFF-induced proliferation in a concentration-dependent manner (IC50 of 0.064 nM). Tibulizumab simultaneously binds and blocks both BAFF and IL-17[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
In cynomolgus monkey, Tibulizumab (i.v, 0.3, 1, 5, or 20 mg/kg; or s.c, 5 mg/kg) suppresses B cell development and survival and remains functionally intact in circulation, with a prolonged half-life[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Essai clinique
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG4-kappa-[scFv-heavy-kappa]2
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized BAFF/TNFSF13B Protein, Human (CHO, HY-P7003) can bind Tibulizumab. The EC50 for this effect is 36.68 ng/mL. -
Immobilized IL-17A Protein, Human (HEK293, His, HY-P70527) can bind Tibulizumab. The EC50 for this effect is 19.5 ng/mL.
Chemical Information
-
CAS No. 1849636-24-3
-
Appearance Liquid
-
Masse moléculaire 201.43 kDa
-
Color Colorless to light yellow
-
SMILES
[Tibulizumab]
-
Synonyms
LY 3090106
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tibulizumab Related Classifications
HY-P99563 Related Classifications
Powered by Bioz